Open Access

Bilateral adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1 (MEN1) and a novel mutation in the MEN1 gene

  • John E Griniatsos1Email author,
  • Nikoletta Dimitriou1,
  • Athanassios Zilos2,
  • Stratigoula Sakellariou3,
  • Konstantinos Evangelou3,
  • Smaragda Kamakari4,
  • Penelope Korkolopoulou3 and
  • Gregory Kaltsas2
World Journal of Surgical Oncology20119:6

https://doi.org/10.1186/1477-7819-9-6

Received: 22 March 2010

Accepted: 25 January 2011

Published: 25 January 2011

Abstract

The incidence of adrenal involvement in MEN1 syndrome has been reported between 9 and 45%, while the incidence of adrenocortical carcinoma (ACC) in MEN1 patients has been reported between 2.6 and 6%. In the literature data only unilateral development of ACCs in MEN1 patients has been reported. We report a 31 years-old female MEN1-patient, in whom hyperplasia of the parathyroid glands, prolactinoma, non functioning pancreatic endocrine carcinoma and functioning bilateral adrenal carcinomas were diagnosed. Interestingly, a not previously described in the literature data, novel germline mutation (p.E45V) in exon 2 of MEN1 gene, was detected. The association of exon 2 mutation of the MEN1 gene with bilateral adrenal carcinomas in MEN1 syndrome, should be further investigated.

Introduction

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder with penetrance reaching 100% with age [1].

It is characterized by parathyroid glands hyperplasia, anterior pituitary gland tumours and pancreatic islets tumours [2]. However, other endocrine and non-endocrine lesions, such as carcinoids of the bronchi [3], gastrointestinal tract [4] and thymus [5], lipomas, angiofibromas and collagenomas [6, 7] can also occur with low frequency, while combinations of more than twenty different endocrine and non-endocrine tumours and lesions have been reported [812].

A simple definition of MEN 1 can not cover all index cases and all families. As a practical definition, sporadic MEN1 is characterised by the occurrence of primary tumours involving two of the three main MEN1 related endocrine tissues within a single patient, while familial MEN1 is defined as at least one MEN1 case plus at least one first degree relative with one of those three tumors [13].

The incidence of adrenal lesions in MEN1 patients varies between 9 and 45% [1420] and they usually develop in patients with mutations in exons 2 and 10 [18]. Other authors stated that they are mainly unilateral (55-79%) [18, 2022], others addressed them as mainly bilateral (60%) [15], but all agree that the majority of these lesions are hyperplastic and nonfunctioning, causing minimal morbidity. Functioning tumors like pheochromocytoma or tumors causing hypercortisolemia and hyperaldosteronism are rare manifestations of MEN1 [23]. The incidence of adreonocortical carcinoma (ACC) in MEN1 patients has been reported between 2.6 [20]and 6% [17, 18, 22]. Although involvement of the adrenal gland has been reported in approximately 40% of MEN1 patients and has been found to represent bilateral hyperplasia, adenoma and in a few cases carcinoma, bilateral adrenal carcinoma has not been previously reported.

Herewith, we report a 31 years-old female patient with sporadic form of MEN1 in whom functioning bilateral adrenocortical carcinomas were diagnosed. Interestingly enough, a novel germline mutation in exon 2 of MEN1 gene, was detected.

Case Report

A 31 years-old female patient with the preoperative diagnosis of MEN1, was referred by the Endocrinologists to the 1st Department of Surgery, for further evaluation and treatment.

On clinical examination, centripetal obesity, moon face, fat deposition over the thoracocervical spine (buffalo hump), excessive terminal hair in various parts of her body and four angiofibromas in her face, were observed. Her arterial blood pressure was moderately abnormal (155/80 mmHg), while she reported menstrual irregularity (infrequent uterine bleeding) and easy bruising. She was suffering from diabetes mellitus since 2002 and she was currently on glargine insulin, whereas she reported having been prescribed Dopamine agonists for her pituitary prolactinoma lesion. Her family history was insignificant

The preoperative imaging investigation of the patient included: magnetic resonance imaging (MRI) of the head disclosing a 1.4 × 1.3 cm pituitary adenoma, cervical ultrasound and Tc99 m Sestamibi-scans both disclosing hyperplasia of the parathyroid glands, abdominal MRI scan and endoscopic ultrasound (EUS) both disclosing a 4.5 × 3.0 cm tumor in the body and tail of the pancreas, fine needle aspiration biopsy (FNAB) of the pancreatic tumor under EUS guidance concluding in histological findings compatible to neuroendocrine tumor, somatostatin receptor imaging with Indium 111 (OctreoScan®) disclosing radionuclide material uptake in the left upper quadrant of the abdominal cavity at some point between the left lobe of the liver and the spleen, while in the abdominal MRI scan bilateral adrenal tumors (right adrenal 8.0 Χ 4.5 cm and left adrenal 7.5 × 5.5 cm) (Figure 1), as well as a fully calcified ectopic left kidney into the pelvis, were detected. Finally, a DMSA renal scan disclosed only 17% renal function of the ectopic left kidney.
Figure 1

MRI scan of the upper abdomen disclosing bilateral adrenal tumors.

The preoperative hormonal evaluation of the patient is presented in Table 1. She was further submitted to an Overnight Dexamethasone Suppression Test (ODST), which failed to suppress the morning cortisol levels- which were 627 nM/L (< 50 nM/L), whereas the Urinary Free Cortisol levels were elevated- 473 μg/24h (55-286), signifying hyper-cortisolism. The ODST, in concordance with the ACTH level, unmasked a Cushing syndrome caused due to adrenal production of cortisol. Moreover, the possibility of adrenocortical carcinoma was considered high in the light of the high levels of androgens. Due to moderate high levels of arterial blood pressure (155/80 mmHg), she had her 24 hours urine output collected. 800mL of urine were collected and the laboratory results were as follows: Adrenaline 3 μg/24h (1.7-22.4), Noradrenaline 29 μg/24h (12-85), Metanefrine 337 μg/24h (100-800), Normetanefrine 298 μg/24h (88-444), VMA 4 μg/24h (1.8-6.7) and Dopamine 47 μg/24h (65-400).
Table 1

Preoperative and postoperative serum hormonal evaluation of the patient

Parameter

Normal values

Preoperative value

Postoperative value

ACTH

1-50 pg/ml

0.23

 

Cortisol

260-720 nM

834

 

Prolactin

2.7-20 ng/ml

25.7

 

Calcium

8.6-10.2 mg/dl

9.8

 

PTH

8-76 pg/ml

107

 

GH

0-10 μIU/ml

12

 

IGF

114-492 ng/ml

847

 

FSH

1.8-9.4 mIU/ml

0.42

 

LH

0.8-10.4 mIU/ml

1.1

 

TSH

0.3-4 mU/l

1.65

 

Testosterone

0.1-0.8 ng/ml

2

0.1

Δ4 Androstendione

0.5-4.7 ng/ml

14.7

0.38

DHEAs

99-340 μg/dl

950

0.01

Phosphorus

2.7-4.5 mg/dl

2.7

 

CgA

19-98 ng/ml

187

 

CA-125

< 30 U/ml

227

40

After the completion of the imaging investigation and the laboratory evaluation, the diagnosis of sporadic form of MEN1 syndrome consisting of: (i) a 1.4 × 1.3 cm prolactine producing pituitary adenoma, (ii) primary hyperparathyroidism due to hyperplasia of the parathyroid glands, (iii) a 4.5 × 3.0 cm non functioning endocrine tumor in the body and tail of the pancreas and (iv) functioning bilateral adrenal tumors, was established.

The patient was submitted to an exploratory laparotomy through a bilateral subcostal incision. She underwent distal pancreatectomy, splenectomy, bilateral adrenalectomy and nephrectomy of the ectopic left kidney. Parathyroidectomy was postponed until the development of clinical or laboratory findings compatible to hyperparathyroidism. The patient had an uneventful postoperative recovery and she was discharge on the 7th postoperative day.

The histological findings were as follows: Distal pancreas (size 9.5 × 5.1 × 2.8 cm). Grossly, the pancreatic tissue exhibited multiple cystic and hemorrhagic lesions ranging from 0.3 to 2 cm in maximum diameter. In the peripancreatic fat five lymphnodes measuring 0.4 to 0.6 cm, were detected. Microscopically, the pancreatic lesions corresponded to neoplastic tissue consisting of uniform neoplastic cells with scant eosinophilic cytoplasm and stippled nuclei, arranged in nests and trabecula. There was mild to moderate nuclear atypia and the mitotic figures were less than 2 per 10 HPF (magnification X40). Neoplastic emboli in pancreatic vessels, as well as tumor nests in the peripancreatic fat were also evident. The tumor appeared to extend within less than 0.3 cm of the surgical margins. The resected lymphnodes were free of metastatic deposits. The neoplastic cells exhibited immunopositivity for neuroendocrine markers (chromogranin and synaptophysin), while the proliferation index assessed by Ki-67 immunohistochemistry was about 5%. Taking into account the above histological observations (especially that the proliferation index was about 5%) as well as the data from the literature, the diagnosis of well-differentiated endocrine carcinoma of the pancreas was established.

Both adrenals glands. The left one weighed 250 gr, measured 10.1 × 7.3 × 4.5 cm and upon sectioning, a well circumscribed brownish tumor with central calcification sizing 7.5 × 5.5 × 4.1 cm, was found. The right adrenal gland weighed 120gr and measured 10.5 × 5.5 × 3.7 cm. Gross examination revealed the presence of a tumor measuring 8 × 4 × 3 cm, with features similar to those of the left gland, but without central calcification. Histologically, both adrenal tumors showed features of adrenocortical neoplasms. The neoplastic population consisted of round to oval cells, with scant eosinophilic cytoplasm and moderate to marked nuclear pleomorphism, arranged in a loose growth pattern (Figure 2). Abnormal caryokinesis and invasion of venous and sinusoid vessels were also observed. Necrotic areas were present only in the tumor of the left adrenal gland. Immunohistochemically, the cells were MelanA and synaptophysin immunopositive. No immunostaining for cytoceratin, chromogranin, EMA and CEA was observed. The remaining non-neoplastic adrenal tissue showed nodular hyperplasia. Based on the above findings, both tumors corresponded to adrenocortical neoplasms with malignant potential, according to Weiss's criteria.
Figure 2

Histological section (H&E counterstain) of the adrenocortical neoplasm in the left adrenal gland, depicting cells with moderate to marked nuclear pleomorphism (magnification X200).

Following these results, the patient as well as her mother and her sister were submitted to genetic test for MEN1. A germline p.E45V mutation in exon 2 of the MEN1 gene was detected, while none of the rest members of the family expressed any genetic abnormality.

Due to the bilateral adrenalectomy she was prescribed on Hydrocortisone and Flurohydrocortisone repletion therapy. Her postoperative hormonal evaluation, soon after having been discharged, is presented in Table 1.

Discussion

In the present report we describe a young female MEN1-patient, in whom apart from the prolactine producing pituitary adenoma, the hyperplasia of the parathyroid glands and the well-differentiated non functioning pancreatic endocrine carcinoma, functioning bilateral adrenocortical carcinomas were diagnosed. A not previously described, novel germline mutation (p.E45V) in exon 2 of MEN1 gene was detected in the postoperative genetic test for MEN1.

MEN1 is a tumor suppressor gene located at chromosome 11q13 loci, encoding a 67 kD nuclear protein of 610 amino acids, called menin [24]. Various types of mutations scattered throughout the 10 coding exons of the MEN1 gene inactivate the MEN1 gene.

Knudson's two-hit model for tumorigenesis [10] addresses that the first hit can take place either in germline or in somatic tissue and compromise a small number of bases. The mutations are distributed across the MEN1 reading frame, resulting in a great deal of novel mutations, approximately 50%, in the index cases. Mostly, they result in premature truncation of DNA sequence, inactivating menin protein. The second hit is usually a large chromosomal deletion, which lives no normal functional allele. The second hit is in somatic tissue and in most cases occurs postnataly.

The first clinical manifestation of MEN1 is hyperparathyroidism, mainly due to multiglandular hyperplasia, which usually affects more than 95% of all MEN1 patients [25]. Although there is no doubt that total parathyroidectomy constitutes the treatment of choice for symptomatic hypercalcaemic MEN1 patients [2], the decision for the timing for the parathyroid surgery should take under account the severity of the PHPT symptoms, the circulating PTH and calcium levels, the presence of MEN1-associated endocrinopathies, especially the Zollinger-Ellison syndrome (ZES) and the patient's age [26]. Since the patient we describe, was asymptomatic, had no evidence of ZES, meeting only one (the age) of the proposed by the NIH criteria for the treatment of asymptomatic primary hyperparathyroidism [27], the parathyroidectomy was postponed for the future.

Pancreatic tumours occur in about 30-75% of MEN1 patients and are the second commonest clinical manifestation of MEN1 [28]. One third of pancreatic tumours are non functioning and clinically silent, but the majority of them produce excessive amounts of hormones such as gastrin, insulin, glucagon, somatostatin, neurotensin or vasoactive intestinal polypeptide and are associated with distinct clinical syndromes [2]. Pancreatic tumours can be multiple and scattered throughout the whole pancreas, ranging in size from micro-adenomas (slightly larger than unaffected islets) to macro-adenomas larger than 0.5 cm [26]. Endoscopic ultrasound (EUS) constitutes the most sensitive imaging method for the detection of small pancreatic endocrine tumours in asymptomatic MEN1 patients (sensitivity > 75%), while the combination of EUS with Octreoscan scintigraphy, increases the pancreatic tumoural detection rate to 90% [29]. As general recommendation, patients with positive imaging studies and no evidence of unresectable metastases, should undergo surgical exploration with intraoperative ultrasound [10]. Surgery is always indicated for hormonal producing tumours, while for asymptomatic patients pancreatic surgery can be decided when the size of the lesion approaches 2 cm [26]. It is generally accepted that large tumours in the pancreatic body or tail should be treated by distal pancreatectomy and splenectomy [30]. The preoperative laboratory and imaging with EUS and Octreoscan work up of the patient we describe, disclosed a non hormonal producing but greater than 2 cm pancreatic tail tumour with no evidence of metastatic disease. Thus, the patient underwent an exploratory laparotomy, the intraoperative ultrasonography did not disclosed any other pancreatic lesion and distal pancreatectomy and splenectomy were performed.

The incidence of pituitary adenomas in MEN1 patients varies between 10 and 60% [13], while their symptoms depend on the type and the amount of the pituitary hormone secretion and/or the compression effects due to the size of the tumour [26]. Pituitary tumours can be successfully managed by drug therapy, reserving surgery and/or radiotherapy for large tumours or irresectable residual disease [2]. The lack of compression symptoms explains why the patient we describe, was treated conservatively.

Regarding the adrenocortical lesions, DNA analysis for allelic loss at the MEN1 locus shown no loss of heterozygosity [15, 31], probably suggesting that they are not a direct result of inactivation of the MEN1 gene.

Since the malignant potential of MEN1-related adrenal neoplasia is of important clinical significance, close biochemical and radiologic follow-up is recommended. Newly diagnosed adrenal lesions should undergone a control investigation after 6 months and in case of a stable lesion, control intervals of 2 years seem to be sufficient [32]. Adrenal lesions smaller than 3 cm are usually asymptomatic and endocrine-inactive with low malignant potential [32]. Although general agreement does not exist, several authors [2, 18, 22] recommend that adrenocortical tumours greater than 3 cm in diameter or growing lesion [32] should be surgically removed because of their malignant potential. Because both adrenal lesions in the presented case were greater than 3 cm, bilateral adrenalectomy was performed.

In the patient we describe, a non functional, fully calcified ectopic pelvic kidney was also detected and surgically removed. Since ectopic kidneys are more susceptible to diseases such as nephrolithiasis, hydronephrosis, injury of aberrant vessels or overlying abdominal viscera and nerves or malignancy than the normally positioned ones, a non functional pelvic kidney requires removal [33].

Preoperatively, the patient we describe, had elevated (7.5-fold) serum CA-125 levels. It is well known the high false positive rate and the poor sensitivity and specificity of the CA-125. Although cardiovascular, lung and chronic liver diseases are the most frequent diagnoses in patients with increased CA-125, other intra-abdominal non-malignant non-hepatic diseases can also cause elevation of the CA-125 [34], as in the present case.

Many proteins that localize to the nucleus contain a polybasic motif, the Nuclear Localization Signal (NLS), which is necessary for proper nuclear targeting. Menin contains two NLSs. Both NLS-1 (amino acid 479-497) and NLS-2 (amino acids 588-608) are present in the C-fourth of menin [35]. Menin binds to JunD transcription factor, a member of Activator Protein 1 family. JunD regulates transcription from certain promoters by binding to TRE consensus. Menin-JunD interaction involves the N-terminus (amino acids 1-40) and midregion (amino acids 323-428) of Menin and requires the N-terminus of JunD (amino acids 8-70). Menin's tumor suppressor involves direct binding to JunD and inhibition of JunD activated transcription [36].

The patient we describe harbors the germline p.E45V mutation of the MEN1 gene which, to the best of our knowledge, has not been previously described in the literature data. It is a point mutation in exon 2 of MEN1 gene, in nucleotide 134 substituting Adenosine to Thymine, changing the Glutamic acid (GAG) to Valine (GTC) in the menin molecule. Although, pathogenetic mutations of glutamic acid either to lysine (p.E45K) or glykine (p.E45G) or alanine (p.E45A), have been previously described [37], the close proximity of this amino acid (amino acid 45) to the area (amino acids 1-40) of menin molecule responsive for Menin-JunD interaction, poses a possible explanation of the present tumorgenesis by disrupting Menin-JunD interaction, finally affecting the tumor suppression function.

In conclusion, we present a MEN1 patient with the novel p.E45V mutation in the exon 2 of the MEN1 gene, in whom bilateral ACC was detected. Whether this novel mutation predisposed to bilateral ACC development or whether bilateral ACC can also occur in MEN1 patients, remains to be proved.

Declarations

Authors’ Affiliations

(1)
1st Department of Surgery, Medical School, University of Athens
(2)
Division of Endocrinology, Department of Pathologic Physiology Medical School, University of Athens
(3)
Department of Pathology, Medical School, University of Athens
(4)
BioGenomica Genetic Tests Center

References

  1. Marx SJ, Simonds WF: Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocrine Rev. 2005, 26: 615-661. 10.1210/er.2003-0037.View ArticleGoogle Scholar
  2. Marini F, Falchetti A, Del Monte F: Multiple endocrine neoplasia type 1. Orphanet Journal of Rare Diseases. 2006, 1: 38-10.1186/1750-1172-1-38.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Debelenko LV, Brambilla E, Agarwal SK, Swalwell JI, Kester MB, Lubensky IA, Zhuang Z, Guru SC, Manickam P, Olufemi SE, Chandrasekharappa SC, Crabtree JS, Kim YS, Heppner C, Burns AL, Spiegel AM, Marx SJ, Liotta LA, Collins FS, Travis WD, Emmert-Buck MR: Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet. 1997, 6: 2285-2290. 10.1093/hmg/6.13.2285.View ArticlePubMedGoogle Scholar
  4. Debelenko LV, Emmert-Buck MR, Zhuang Z, Epshteyn E, Moskaluk CA, Jensen RT, Liotta LA, Lubensky IA: The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology. 1997, 113: 773-781. 10.1016/S0016-5085(97)70171-9.View ArticlePubMedGoogle Scholar
  5. Teh BT: Thymic carcinoids in multiple endocrine neoplasia type 1. J Intern Med. 1998, 243: 501-504. 10.1046/j.1365-2796.1998.00329.x.View ArticlePubMedGoogle Scholar
  6. Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M: Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol. 1997, 133: 853-857. 10.1001/archderm.133.7.853.View ArticlePubMedGoogle Scholar
  7. Pack S, Turner ML, Zhuang Z, Vortmeyer AO, Böni R, Skarulis M, Marx SJ, Darling TN: Cutaneous tumors in patients with multiple endocrine neoplasia type 1 show allelic deletion of the MEN1 gene. J Invest Dermatol. 1998, 110: 438-440. 10.1046/j.1523-1747.1998.00140.x.View ArticlePubMedGoogle Scholar
  8. Agarwal SK, Lee Burns A, Sukhodolets KE, Kennedy PA, Obungu VH, Hickman AB, Mullendore ME, Whitten I, Skarulis MC, Simonds WF, Mateo C, Crabtree JS, Scacheri PC, Ji Y, Novotny EA, Garrett-Beal L, Ward JM, Libutti SK, Richard Alexander H, Cerrato A, Parisi MJ, Santa Anna-AS, Oliver B, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ: Molecular pathology of the MEN1 gene. Ann NY Acad Sci. 2004, 1014: 189-198. 10.1196/annals.1294.020.View ArticlePubMedGoogle Scholar
  9. Marx SJ: Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer. 2005, 5: 367-375. 10.1038/nrc1610.View ArticlePubMedGoogle Scholar
  10. Doherty GM: Multiple endocrine neoplasia type 1. J Surg Oncol. 2005, 89: 143-150. 10.1002/jso.20181.View ArticlePubMedGoogle Scholar
  11. Carrasco CA, González AA, Carvajal CA, Campusano C, Oestreicher E, Arteaga E, Wohllk N, Fardella CE: Novel intronic mutation of MEN1 gene causing familial isolated primary hyperparathyroidism. J Clin Endocrinol Metab. 2004, 89: 4124-4129. 10.1210/jc.2003-032101.View ArticlePubMedGoogle Scholar
  12. Hao W, Skarulis MC, Simonds WF, Weinstein LS, Agarwal SK, Mateo C, James-Newton L, Hobbs GR, Gibril F, Jensen RT, Marx SJ: Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab. 2004, 89: 3776-3784. 10.1210/jc.2003-031511.View ArticlePubMedGoogle Scholar
  13. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA, Marx SJ: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001, 86: 5658-5671. 10.1210/jc.86.12.5658.View ArticlePubMedGoogle Scholar
  14. Burgess JR, Harle RA, Tucker P, Parameswaran V, Davies P, Greenaway TM, Shepherd JJ: Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch Surg. 1996, 131: 699-702.View ArticlePubMedGoogle Scholar
  15. Skogseid B, Larsson C, Lindgren PG, Kvanta E, Rastad J, Theodorsson E, Wide L, Wilander E, Oberg K: Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1992, 75: 76-81. 10.1210/jc.75.1.76.PubMedGoogle Scholar
  16. Carty SE, Helm AK, Amico JA, Clarke MR, Foley TP, Watson CG, Mulvihill JJ: The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery. 1998, 124: 1106-1114. 10.1067/msy.1998.93107.View ArticlePubMedGoogle Scholar
  17. Skogseid B, Rastad J, Gobl A, Larsson C, Backlin K, Juhlin C, Akerström G, Oberg K: Adrenal lesion in multiple endocrine neoplasia type 1. Surgery. 1995, 118: 1077-1082. 10.1016/S0039-6060(05)80117-5.View ArticlePubMedGoogle Scholar
  18. Langer P, Cupisti K, Bartsch DK, Nies C, Goretzki PE, Rothmund M, Röher HD: Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg. 2002, 26: 891-896. 10.1007/s00268-002-6492-4.View ArticlePubMedGoogle Scholar
  19. Barzon L, Pasquali C, Grigoletto C, Pedrazzoli S, Boscaro M, Fallo F: Multiple endocrine neoplasia type 1 and adrenal lesions. J Urol. 2001, 166: 24-27. 10.1016/S0022-5347(05)66068-5.View ArticlePubMedGoogle Scholar
  20. Gibril F, Schumann M, Pace A, Jensen RT: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore). 2004, 83: 43-83. 10.1097/01.md.0000112297.72510.32.View ArticleGoogle Scholar
  21. Chico A, Gallart L, Martín-Campos JM, Catasús L, Mayoral C, Mato E, Tortosa F, Bernà L, Rodríguez-Espinosa J, Blanco-Vaca F, Matías-Guiu X, de Leiva A, Mauricio D: Genetic, clinical, and biochemical analysis of unrelated Spanish families with multiple endocrine neoplasia type I. Endocr Pract. 2000, 6: 13-19.View ArticlePubMedGoogle Scholar
  22. Waldmann J, Bartsch DK, Kann PH, Fendrich V, Rothmund M, Langer P: Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch Surg. 2007, 392: 437-443. 10.1007/s00423-006-0124-7.View ArticlePubMedGoogle Scholar
  23. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, Marx SJ: Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metabol. 2001, 12: 173-178. 10.1016/S1043-2760(00)00372-6.View ArticleGoogle Scholar
  24. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ: Positional cloning of the gene for multiple endocrine neoplasia--type 1. Science. 1997, 276: 404-407. 10.1126/science.276.5311.404.View ArticlePubMedGoogle Scholar
  25. Phay EJ, Moley FJ, Lairmore CT: Multiple Endocrine Neoplasias. Semin Surg Oncol. 2000, 18: 324-332. 10.1002/(SICI)1098-2388(200006)18:4<324::AID-SSU7>3.0.CO;2-5.View ArticlePubMedGoogle Scholar
  26. Falchetti A, Marini F, Luzi E, Tonelli F, Brandi ML: Multiple endocrine neoplasms. Best Prac Res Clin Rheumatol. 2008, 22: 149-163. 10.1016/j.berh.2007.11.010.View ArticleGoogle Scholar
  27. Bilezikian JP, Khan AA, Potts JT: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009, 94: 335-339. 10.1210/jc.2008-1763.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Akerstrom G, Hellman P: Surgery on neuroendocrine tumours. Best Prac Res Clin Endocrinol Metabol. 2007, 21: 87-109. 10.1016/j.beem.2006.12.004.View ArticleGoogle Scholar
  29. Rösch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV, Yasuda K, Heyder N, Palazzo L, Dancygier H, Schusdziarra V: Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992, 326: 1721-1726.View ArticlePubMedGoogle Scholar
  30. Lairmore TC, Chen VY, DeBenedetti MK, Gillanders WE, Norton JA, Doherty GM: Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg. 2000, 231: 909-918. 10.1097/00000658-200006000-00016.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Vortmeyer AO, Lubensky IA, Skarulis M, Li G, Moon YW, Park WS, Weil R, Barlow C, Spiegel AM, Marx SJ, Zhuang Z: Multiple endocrine neoplasia type 1: atypical presentation, clinical course, and genetic analysis of multiple tumors. Mod Pathol. 1999, 12: 919-924.PubMedGoogle Scholar
  32. Schaefer S, Shipotko M, Meyer S, Ivan D, Klose KJ, Waldmann J, Langer P, Kann PH: Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Eur J Endocrinol. 2008, 158: 699-704. 10.1530/EJE-07-0635.View ArticlePubMedGoogle Scholar
  33. Cinman NM, Okeke Z, Smith AD: Pelvic kidney: associated diseases and treatment. J Endourol. 2007, 21: 836-842. 10.1089/end.2007.9945.View ArticlePubMedGoogle Scholar
  34. Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, Cubedo R, Carcereny E, Bonilla F, Gea T: Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies. Ann Surg Oncol. 2003, 10: 150-154. 10.1245/ASO.2003.05.015.View ArticlePubMedGoogle Scholar
  35. Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, Chandrasekharappa SC: Menin, the product of MEN1 gene, is a nuclear protein. Proc Natl Acad Sci. 1998, 95: 1630-1634. 10.1073/pnas.95.4.1630.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL: Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell. 1999, 96: 143-152. 10.1016/S0092-8674(00)80967-8.View ArticlePubMedGoogle Scholar
  37. Lemos MC, Thakker RV: Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008, 29: 22-32. 10.1002/humu.20605.View ArticlePubMedGoogle Scholar

Copyright

© Griniatsos et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement